Novartis tops 2026 Access to Medicine Index, leading in all technical areas for expanding global medicine access.

Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with an R&D score nearly double the sector average, reflecting its strong commitment to expanding healthcare access globally. Key achievements include launching Coartem® Baby for malaria in infants, advancing next-gen antimalarial KLU156, and reaching 304 million patients worldwide in 2025. Novartis continues to invest heavily in R&D and partnerships to address diseases in low- and middle-income countries, aiming to improve treatment access and affordability.

Novartis holds a substantial market cap of $307.51 billion as of Nov 10, 2026, 20:12 WIB, with a dividend yield of 2.9% on Pluang. The stock price is USD 163.52, showing a slight 0.10% decrease in the last day. Investors typically hold Novartis shares for about 84 days on the platform, indicating moderate-term interest in this leading healthcare company.